RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Atrium Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.61−0.06 (-0.78%)
Close on Oct 19, 2026
- Market cap
- $130.18M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | After market close | $3.00M | $-1.18 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 14, 2026 | After market close | $19.60M | $-0.97 | – |
Press releases
Announcements Atrium Therapeutics filed with the SEC
Atrium Therapeutics Announces $50 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Atrium Therapeutics Announces FDA Clearance of Investigational New Drug
Other events · EX-99.1 to Form 8-K
Atrium Therapeutics Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
This information statement is being furnished to existing stockholders of Avidity Biosciences, Inc. (“Avidity”) in connection with the pro rata
Regulation FD disclosure · EX-99.1 to Form 8-K